The PE Ratio as of November 2024 (TTM) for I-Mab (IMAB) is -0.47

According to I-Mab’s latest financial reports and current stock price. The company's current PE Ratio is -0.47. This represents a change of -114.69% compared to the average of 3.20 of the last 4 quarters.

I-Mab (IMAB) Historical PE Ratio (quarterly & annually)

How has IMAB PE Ratio performed in the past?

The mean historical PE Ratio of I-Mab over the last ten years is 4.51. The current -0.47 PE Ratio has changed -1141.31% with respect to the historical average. Over the past ten years (40 quarters), IMAB's PE Ratio was at its highest in in the September 2020 quarter at 399.78. The PE Ratio was at its lowest in in the June 2021 quarter at -18.48.

I-Mab (IMAB) PE Ratio by Quarter and Year

Discovering the peaks and valleys of I-Mab PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

I-Mab (IMAB) Average PE Ratio

How has IMAB PE Ratio performed in the past?

The current PE Ratio of I-Mab (IMAB) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

I-Mab (IMAB) PE Ratio vs. Peers

How is IMAB’s PE Ratio compared to its peers?

I-Mab’s PE Ratio is greater than BeiGene, Ltd. (-40.83), less than Krystal Biotech, Inc. (47.62), greater than Immunovant, Inc. (-15.75), greater than Mirati Therapeutics, Inc. (-5.32), greater than Foghorn Therapeutics Inc. (-4.95), greater than Shattuck Labs, Inc. (-0.74), greater than Monte Rosa Therapeutics, Inc. (-4.86), greater than Kymera Therapeutics, Inc. (-21123.12), greater than Nurix Therapeutics, Inc. (-10.06), greater than Lyell Immunopharma, Inc. (-1.36), greater than Cullinan Oncology, Inc. (-6.11), greater than Theseus Pharmaceuticals, Inc. (-3.19), greater than Revolution Medicines, Inc. (-17.52), greater than Gracell Biotechnologies Inc. (-12.33), greater than Design Therapeutics, Inc. (-5.82), greater than Erasca, Inc. (-3.74), greater than Ascendis Pharma A/S (-13.52), greater than Apellis Pharmaceuticals, Inc. (-10.41), greater than Akero Therapeutics, Inc. (-10.95), greater than Blueprint Medicines Corporation (-44.89),

Build a custom stock screener for I-Mab (IMAB) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like I-Mab using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

I-Mab (IMAB) and other stocks custom spreadsheet templates

The easiest way to analyze a company like I-Mab or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.